ISIN:DE000A0STSQ8

EQS-News: M1 Kliniken AG publishes preliminary figures for financial year 2023: M1 continues to grow - sales growth of over 10% to € 316,3 million; EBIT increases by 68% to € 15.7 million

Retrieved on: 
Freitag, Mai 3, 2024
M1, Investment, EBT, Tax, M1 Group, Growth

M1 Kliniken AG publishes preliminary figures for financial year 2023:

Key Points: 
  • M1 Kliniken AG publishes preliminary figures for financial year 2023:
    M1 continues to grow - sales growth of over 10% to € 316,3 million; EBIT increases by 68% to € 15.7 million and the Group's equity increases to € 143.7 million.
  • Strong sales growth of 18% in the Beauty segment from € 60.2 million to € 70.8 million.
  • Berlin, 18.04.2024 –M1 Kliniken AG (ISIN: DE000A0STSQ8) publishes preliminary IFRS figures for the financial year 2023.
  • The M1 Group's consolidated sales increased by 10.9% to € 316.3 million in the 2023 financial year (previous year: € 285.3 million).

EQS-News: M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024

Retrieved on: 
Freitag, Februar 16, 2024
M1, EUR, Growth, Frankfurt Stock Exchange, Policy, M1 Group

M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024

Key Points: 
  • M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024
    The issuer is solely responsible for the content of this announcement.
  • M1 Kliniken AG: Private equity interested in beauty segment, EBITDA of over EUR 27 million expected in 2024
    Berlin, 16 February 2024 - M1 Kliniken AG (ISIN: DE000A0STSQ8) has built up the leading private aesthetic medical service provider in Europe under the "M1 Med Beauty" brand.
  • In the first nine months of 2023, the Beauty segment generated revenue of EUR 53.2 million (+28.5 %) and EBITDA of EUR 16.9 million (+56.6 %).
  • The analysts' forecasts for the current financial year 2024 of M1 Kliniken AG amount to an EBITDA of EUR 27.1 million, an estimate that is also shared by the M1 Management Board.

EQS-News: M1 Kliniken AG: Interesse von Private Equity an Beauty-Segment, EBITDA von über 27 Mio. EUR in 2024 erwartet

Retrieved on: 
Freitag, Februar 16, 2024
M1, Krankenhaus, Interesse, Equity, MED, Dienstleister, Unternehmen, Wachstum, Marktzutritt, Markt, Medizin, Meilenstein, Fokus, Gruppe, Sinne, Shareholder, Gesellschaft, Option, Zusammenhang, Investmentbank, Marktkapitalisierung, Management, Transaktion, Bewertung, Prognose, Analyst, Seite, Vorstand, Prozess, Stadium, Daten, Angebot, Bereich, Unternehmensgruppe, Produkt, Dienstleistung, Behandlung, Chirurgie, Betten, Einrichtung, Art, Internationalisierung

EQS-News: Vorstand der M1 Kliniken AG erwirbt 1,5 Mio. Aktien der Gesellschaft und plant ein Uplisting in den Prime Standard

Retrieved on: 
Dienstag, Februar 6, 2024
Vorstand, M1, Krankenhaus, Aktie, Gesellschaft, Prime, Standard, Herr, Strauß, MPH, Health, Care, Wunsch, Ausrichtung, Entwicklung, Unternehmen, Beteiligung, Anleger (Finanzmarkt), Wachstum, Unternehmensgruppe, Fokus, Kommunikation, Schwerpunkt, Angebot, Bereich, Produkt, Dienstleistung, MED, Behandlung, Chirurgie, Betten, Einrichtung, Art, Internationalisierung

EQS-News: Management Board of M1 Kliniken AG acquires 1.5 million shares in the company and plans an uplisting to the Prime Standard

Retrieved on: 
Dienstag, Februar 6, 2024
Policy, Growth, Communication, Security (finance)

The two members of the Management Board of M1 Kliniken AG, Mr Attila Strauss and Mr Kilian Brenske, acquired a total of 1.5 million shares in the company from MPH Health Care AG on 2 February 2024.

Key Points: 
  • The two members of the Management Board of M1 Kliniken AG, Mr Attila Strauss and Mr Kilian Brenske, acquired a total of 1.5 million shares in the company from MPH Health Care AG on 2 February 2024.
  • The Co-CEOs justify the share purchase with their confidence in the long-term growth prospects of M1 Kliniken AG and the desire to participate even more strongly in the strategic direction and development of the company.
  • Co-CEO Kilian Brenske explains: "We are firmly convinced that our investment will further strengthen investor confidence.
  • Co-CEO, Attila Strauss, adds: "Intensifying communication with external investors, a shareholder-friendly dividend policy and also a possible uplisting to the Prime Standard will be further focal points."

EQS-News: Invitation to the virtual AlsterResearch Healthcare Pop-Up Conference on 23 January 2024 at 1:30 pm

Retrieved on: 
Dienstag, Januar 30, 2024
Conference

As part of the AlsterResearch Healthcare Pop-Up Conference, we cordially invite you to our virtual roundtable on Tuesday, 23 January 2024 at 13:30 (CET).

Key Points: 
  • As part of the AlsterResearch Healthcare Pop-Up Conference, we cordially invite you to our virtual roundtable on Tuesday, 23 January 2024 at 13:30 (CET).
  • Attila Strauss, Co-CEO of M1 Kliniken AG, and Kilian Brenske, Co-CEO of M1 Kliniken AG, will give you a company update and an outlook for the coming months in a presentation.
  • Afterwards, the gentlemen will be available to answer your questions.
  • You can register for the AlsterResearch Healthcare Pop-Up Conference at the following link:

EQS-News: M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result

Retrieved on: 
Samstag, Dezember 30, 2023
Growth, EUR, M1, M1 Group, Lithium

M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result

Key Points: 
  • M1 Kliniken AG publishes figures for the third quarter 2023: Further strong growth and doubling of the operating result
    The issuer is solely responsible for the content of this announcement.
  • M1 Kliniken AG publishes figures for the third quarter 2023:
    Group sales increase by over 10% to EUR 236.6 million in the first nine months of the 2023 financial year (previous year: EUR 214.2 million).
  • The operating result (Group EBIT) increases by over 98% to EUR 12.9 million (previous year: EUR 6.5 million).
  • EBIT rose by 98.2% to EUR 12.94 million (previous year: EUR 6.53 million), an increase of EUR 6.4 million.